DOCSLIB.ORG

(UGT1A) GENE FAMILY MEMBERS by VITAMIN D RECEPTOR Khanyile

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(UGT1A) GENE FAMILY MEMBERS by VITAMIN D RECEPTOR Khanyile THE REGULATION OF URIDINE 5’DIPHOSPHO- GLUCURONOSYLTRANSFERASE 1A (UGT1A) GENE FAMILY MEMBERS BY VITAMIN D RECEPTOR Khanyile Merritt Dube BSc (Hons) Biomedical Sciences Research conducted within The School of Biomedical Science Faculty of Life and Health Sciences University of Ulster A thesis submitted for the degree of Doctor of Philosophy October 2020 I confirm that the word count of this thesis is less than 100,000 words 1 Contents DECLARATION 13 ACKNOWLEDGEMENTS 14 SUMMARY 15 ABBREVIATIONS 17 1: Chapter 1: Introduction 1.1.1 Vitamin D and its biosynthesis 25 1.1.2 Hepatic and Renal Metabolism of Vitamin D 25 1.1.3.Homeostatic control of Vitamin D 26 1.2 Actions of Vitamin D 28 1.2.1 Regulation of Mineral Homeostasis (Classical Role of Vitamin D) 1.3 Clinical Recommendation of Vitamin D 29 1.4 Genomic Mechanisms of Vitamin D 31 1.4.1 Introduction to Nuclear Receptors 31 1.4.2 Vitamin D Receptor 35 1.4.3 Genome-wide studies of VDR/RXR binding in various cell lines 35 1.5 Non-classical roles of Vitamin D 38 1.5.1 Vitamin D and Immunology 38 1.5.2 Vitamin D and Cardiovascular Diseases 38 1.5.3 Vitamin D and Neurodegenerative Disorders 39 1.5.4 Vitamin D and Malignancies 39 1.5.5 Vitamin D and Metabolism 40 1.6. UDP-Glucuronosyltransferases (UGTs) 42 2 1.6.1 UGT1A Tissue Distribution 45 1.6.2 Transcriptional Regulation of UGT1A gene family members 47 1.6.3 UGT1A Clinical Relevance 50 1.7 NRF2: The master regulator of oxidative stress 53 1.7.1 NRF2 Discovery and Function 54 1.7.2 NRF2 activation and repression 57 1.7.3 NRF2 and Target genes 58 1.7.4 NRF2 in Health and Disease 59 1.8 Vitamin D – ‘A custodian for phenotypic stability’ 60 1.9 Research Aims and Objectives 64 2 Chapter 2: Material and Methods 2.1 Reagents 67 2.2 Cell Culture 67 2.2.1 LS180 cells 67 2.2.2 Human Embryonic Kidney cells (HEK293 cells) 68 2.2.3 LNCaP cells 68 2.2.4 Sub-culture routine 68 2.2.5 Cell Storage 68 2.2.6 Thawing cells 69 2.2.7 Cell Density 69 2.2.8 Dosage with Ligands 70 2.3 Polymerase Chain Reaction (PCR) 71 2.3.1 RNA Extraction 71 2.3.2 Ethanol Precipitation 72 3 2.3.3 cDNA Synthesis 72 2.3.4 Primer Design and Preparation 73 2.3.5 Endpoint PCR 75 2.3.6 Gel Electrophoresis 76 2.3.7 Real Time PCR 76 2.4 DNA Extraction 78 2.4.1 DNA Amplification 79 2.4.2 Gel Excision and DNA purification 80 2.5 Western Blot Analysis 81 2.5.1 Extraction Protein from Whole Cell Lysates 81 2.5.2 Extraction of Protein from Microsomal fractions 81 2.5.3 Quantification of Protein 82 2.5.4 Blotting 82 2.5.5 Probing with antibody 83 2.6 Glucuronidation Activity Assay 85 2.6.1 Preparation of cell homogenates 85 2.6.2 Glucuronidation Assay using UGT-glo 85 2.6.3 UGT Activity Detection 86 2.7 Reporter Activity Assay 86 2.7.1 Plasmids 86 2.7.2 Transformation of plasmids into Library Efficiency® DH5α E.coli (Invitrogen) 88 2.7.3 Transfection Methodology 89 2.7.3.1 Lipofectamine Transfection 89 4 2.7.3.2 Calcium Phosphate Transfection 89 2.7.4 Reporter Assay Reading 90 2.8 Site-directed Mutagenesis 90 2.9 Sequencing 92 2.10 Cell Viability Assay 94 2.11 Growth Inhibition Assay 94 2.12 In Silico Analysis 94 2.12.1 In Silico Screening for putative response elements 94 2.13 CloneJet PCR cloning 95 2.13.1 Ligation Formula 95 2.13.2 Analysis of recombinant clones 96 2.14 Clustered Regulatory Interspaced short palindromic repeats interference (CRISPRi) engineering 97 2.14.1 Single guide RNA design 97 2.14.2 Ribonucleoprotein (RNP) complex formation and Lipofection 98 3 Chapter 3 Induction of UGT1A gene family members by Vitamin D Receptor 3.1 Introduction 102 3.2 Results 107 3.2.1 Vitamin D regulates the expression of UGT1A gene family members 107 3.3 VDR is an autonomous regulator of the UGT1A gene 112 3.4 Direct repeat 3 (DR3) motif within the UGT1A1 proximal gene promoter is a functional Vitamin D response element (VDRE). 116 5 3.5 Vitamin D enhances UGT1A protein expression in LS180 cells 122 3.6 Vitamin D increases glucuronidation activity in LS180 cells 126 3.7 Discussion 128 3.8 Summary of key findings 135 4 Chapter 4: Examining the cross-talk between Vitamin D Receptor (VDR) and nuclear factor erythroid 2-related factor 2 (NRF2) signaling pathways 4.1 Introduction 137 4.2 Results 139 4.2.1 Cell Viability Assay 139 4.2.2 NRF2 and VDR ligands induce ARE-signaling in LS180 cells 140 4.2.3 ARE-signaling in Vitamin D pre-treated LS180 cells 143 4.2.4 ARE minimal promoter activity is modulated by NRF2 and VDR ligands 145 4.2.5 The effects of NRF2 and VDR ligands co-treatment in LS180 cells 146 4.2.6 Establishing co-dependency of VDR and NRF2 signaling 149 4.2.7 Effects of VDR and NRF2 ligands in combinatorial Treatment 151 4.2.8 VDRE minimal promoter activity is suppressed by sulphorafane (SFN) 154 4.2.9 Vitamin D pre-treatment enhances NRF2-mediated 6 UGT1A1 activity 156 4.2.10 Modulation of detoxification products in pre-treated LS180 cells 159 4.2.11 Anti-tumoural actions of VDR and NRF2 signaling Pathways 158 4.3 VDR and NRF2 signaling interplay in LNCaP cells 168 4.3.1 NRF2 and VDR interplay in LNCaP cells 168 4.3.2 VDR and NRF2 ligands inhibit LNCaP and LS180 cell growth 173 4.4 Discussion 174 4.5 Summary of key findings 184 5 Chapter 5: Characterization of UGT1A loci 5.1 Introduction 186 5.2 Results 190 5.2.1 The UGT1A locus is regulated by novel VDR/RXR binding 190 5.2.2 Characterization of the UGT1A gene using CRISPRi 196 5.3 Discussion 201 5.4 Summary of key findings 205 6 Chapter 6: General Discussion 6.1 Discussion 207 6.2 Clinical Relevance 212 6.3 Limitations of this study 216 7 6.4 Future Experiments 217 6.5 Summary of key findings 219 6.6 Concluding Remarks 220 7 References 221 8 Appendix 263 List of Figures 1: Chapter 1 1.1Chemical Structure and Vitamin D Biosynthesis 27 1.2 Structural organization of VDR 33 1.3 Gene transcription activity 37 1.4 A representation of cellular detoxification 41 1.5 The endoplasmic reticulum (ER) glucuronidation pathway 43 1.6 The Genomic Organization of the UGT1A loci on chromosome 2q37 45 1.7 Differential expression of UGT1A and UGT2B genes in normal tissue 46 1.8 The phenobarbital responsive enhancer module nucleotide sequence 50 1.9 NRF2 structural domain 56 1.10 The domain structure of small Maf proteins 57 1.11 Examples of NRF2 target genes 59 1.12 A proposed model of Vitamin D and NRF2 co-operative effects 63 2 Chapter 2 2.1 The pGL4.37[luc2P/ARE/Hygro] Vector 87 2.2 The pGL3-Basic Luciferase Reporter Vector 88 2.3 UGT1A1 promoter sequence 91 2.4 PJET1.2/blunt is a blunt- end-cloning vector 97 8 2.5 CRISPRi transcriptional silencing model 100 3 Chapter 3 3.1 Gene expression in LS180 cells 107 3.2 UGT1A expression profile in LS180 cells 109 3.3 mRNA expression of VDR target genes in LS180 cells 111 3.4 Time-dependent mRNA expression of UGT1A genes by VDR and PXR ligands. 112 3.5 The UGT1A1 phenobarbital responsive enhancer module 114 3.6 VDR regulates UGT1A1 promoter activity 115 3.6 Identification of a functional VDRE within the UGT1A1 promoter region. 3.7 UGT1A sequence 118 3.8 VDR and PXR share the same DR3-type binding motif within the UGT1A1 promoter region. 120 3.10 Defining the DR3-type motif specificity within the UGT1A1 promoter region 3.11 Western Blot analysis showing UGT1A protein expression in LS180 cells 124 3.12 UGT1A protein expression in LS180 cells by VDR and PXR ligands 125 3.13 Nuclear receptor expression in various cancer cell lines 125 3.14 VDR ligands enhance glucuronidation activity in LS180 cells 127 4 Chapter 4 4.1 Cell Viability of NRF2 ligands in LS180 cells 140 9 4.2 Titration curve of ARE activation in LS180 and HEK293 cells. 142 4.3 ARE activation by NRF2 ligands following pre-treatment in LS180 cells 144 4.4 ARE minimal promoter activity is mediated by NRF2 and VDR ligands. 146 4.5 VDR and NRF2 ligands co-treatment in LS180 cells. 148 4.6 VDR and NRF2 co-dependency in UGT1A1 induction. 150 4.7 Effects of VDR and NRF2 target genes in combinatorial treatments 4.8 VDRE signalling in LS180 cells. 154 4.9 UGT1A1 induction in LS180 cells pre-treated with 1,25D 156 4.10 Effects of VDR and NRF2 target genes in combinatorial treatments 4.11 Effects of VDR and NRF2 target genes in combinatorial treatments 4.12 ARE signalling in LNCaP cells 167 4.13 NRF2 target gene regulation in LNCaP cells pre-treated with 1,25D 170 4.14 VDR target gene regulation in LNCaP cells pre-treated with 1,25D 4.15 Growth inhibition assay in LNCaP and LS180 cells 174 5 Chapter 5 5.1 CRISPRi –based approach model 189 5.2 RSAT output of putative VDREs within UGT1A4 promoter region 5.3 UGT1A loci is regulated by VDR/RXR binding motifs 195 5.4UGT1A plasmid construction by sub-cloning 196 5.5 RT-PCR product of amplified of the 1532by DNA fragment of the UGT1A locus 196 10 5.6 Lipofection procedure for CRISPRi technique.
Load more

Recommended publications
  • Environmental Influences on Endothelial Gene Expression
    ENDOTHELIAL CELL GENE EXPRESSION John Matthew Jeff Herbert Supervisors: Prof. Roy Bicknell and Dr. Victoria Heath PhD thesis University of Birmingham August 2012 University of Birmingham Research Archive e-theses repository This unpublished thesis/dissertation is copyright of the author and/or third parties. The intellectual property rights of the author or third parties in respect of this work are as defined by The Copyright Designs and Patents Act 1988 or as modified by any successor legislation. Any use made of information contained in this thesis/dissertation must be in accordance with that legislation and must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the permission of the copyright holder. ABSTRACT Tumour angiogenesis is a vital process in the pathology of tumour development and metastasis. Targeting markers of tumour endothelium provide a means of targeted destruction of a tumours oxygen and nutrient supply via destruction of tumour vasculature, which in turn ultimately leads to beneficial consequences to patients. Although current anti -angiogenic and vascular targeting strategies help patients, more potently in combination with chemo therapy, there is still a need for more tumour endothelial marker discoveries as current treatments have cardiovascular and other side effects. For the first time, the analyses of in-vivo biotinylation of an embryonic system is performed to obtain putative vascular targets. Also for the first time, deep sequencing is applied to freshly isolated tumour and normal endothelial cells from lung, colon and bladder tissues for the identification of pan-vascular-targets. Integration of the proteomic, deep sequencing, public cDNA libraries and microarrays, delivers 5,892 putative vascular targets to the science community.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Protein Identities in Evs Isolated from U87-MG GBM Cells As Determined by NG LC-MS/MS
    Protein identities in EVs isolated from U87-MG GBM cells as determined by NG LC-MS/MS. No. Accession Description Σ Coverage Σ# Proteins Σ# Unique Peptides Σ# Peptides Σ# PSMs # AAs MW [kDa] calc. pI 1 A8MS94 Putative golgin subfamily A member 2-like protein 5 OS=Homo sapiens PE=5 SV=2 - [GG2L5_HUMAN] 100 1 1 7 88 110 12,03704523 5,681152344 2 P60660 Myosin light polypeptide 6 OS=Homo sapiens GN=MYL6 PE=1 SV=2 - [MYL6_HUMAN] 100 3 5 17 173 151 16,91913397 4,652832031 3 Q6ZYL4 General transcription factor IIH subunit 5 OS=Homo sapiens GN=GTF2H5 PE=1 SV=1 - [TF2H5_HUMAN] 98,59 1 1 4 13 71 8,048185945 4,652832031 4 P60709 Actin, cytoplasmic 1 OS=Homo sapiens GN=ACTB PE=1 SV=1 - [ACTB_HUMAN] 97,6 5 5 35 917 375 41,70973209 5,478027344 5 P13489 Ribonuclease inhibitor OS=Homo sapiens GN=RNH1 PE=1 SV=2 - [RINI_HUMAN] 96,75 1 12 37 173 461 49,94108966 4,817871094 6 P09382 Galectin-1 OS=Homo sapiens GN=LGALS1 PE=1 SV=2 - [LEG1_HUMAN] 96,3 1 7 14 283 135 14,70620005 5,503417969 7 P60174 Triosephosphate isomerase OS=Homo sapiens GN=TPI1 PE=1 SV=3 - [TPIS_HUMAN] 95,1 3 16 25 375 286 30,77169764 5,922363281 8 P04406 Glyceraldehyde-3-phosphate dehydrogenase OS=Homo sapiens GN=GAPDH PE=1 SV=3 - [G3P_HUMAN] 94,63 2 13 31 509 335 36,03039959 8,455566406 9 Q15185 Prostaglandin E synthase 3 OS=Homo sapiens GN=PTGES3 PE=1 SV=1 - [TEBP_HUMAN] 93,13 1 5 12 74 160 18,68541938 4,538574219 10 P09417 Dihydropteridine reductase OS=Homo sapiens GN=QDPR PE=1 SV=2 - [DHPR_HUMAN] 93,03 1 1 17 69 244 25,77302971 7,371582031 11 P01911 HLA class II histocompatibility antigen,
    [Show full text]
  • Regulation of Xenobiotic and Bile Acid Metabolism by the Anti-Aging Intervention Calorie Restriction in Mice
    REGULATION OF XENOBIOTIC AND BILE ACID METABOLISM BY THE ANTI-AGING INTERVENTION CALORIE RESTRICTION IN MICE By Zidong Fu Submitted to the Graduate Degree Program in Pharmacology, Toxicology, and Therapeutics and the Graduate Faculty of the University of Kansas in partial fulfillment of the requirements for the degree of Doctor of Philosophy. Dissertation Committee ________________________________ Chairperson: Curtis Klaassen, Ph.D. ________________________________ Udayan Apte, Ph.D. ________________________________ Wen-Xing Ding, Ph.D. ________________________________ Thomas Pazdernik, Ph.D. ________________________________ Hao Zhu, Ph.D. Date Defended: 04-11-2013 The Dissertation Committee for Zidong Fu certifies that this is the approved version of the following dissertation: REGULATION OF XENOBIOTIC AND BILE ACID METABOLISM BY THE ANTI-AGING INTERVENTION CALORIE RESTRICTION IN MICE ________________________________ Chairperson: Curtis Klaassen, Ph.D. Date approved: 04-11-2013 ii ABSTRACT Calorie restriction (CR), defined as reduced calorie intake without causing malnutrition, is the best-known intervention to increase life span and slow aging-related diseases in various species. However, current knowledge on the exact mechanisms of aging and how CR exerts its anti-aging effects is still inadequate. The detoxification theory of aging proposes that the up-regulation of xenobiotic processing genes (XPGs) involved in phase-I and phase-II xenobiotic metabolism as well as transport, which renders a wide spectrum of detoxification, is a longevity mechanism. Interestingly, bile acids (BAs), the metabolites of cholesterol, have recently been connected with longevity. Thus, this dissertation aimed to determine the regulation of xenobiotic and BA metabolism by the well-known anti-aging intervention CR. First, the mRNA expression of XPGs in liver during aging was investigated.
    [Show full text]
  • Supl Table 1 for Pdf.Xlsx
    BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) Gut Table S1. Proteomic analysis of liver tissues from 4-months old control and LPTENKO mice. Soluble Fraction Gene names LOG2FC CTL1 LOG2FC CTL2 LOG2FC CTL3 LOG2FC KO1 LOG2FC KO2 LOG2FC KO3 t-test adj Pvalue Aass 0.081686519 -0.097912098 0.016225579 -1.135271836 -0.860535624 -1.263037541 0.0011157 1.206072068 Acsm5 -0.125220746 0.071090866 0.054129881 -0.780692107 -0.882155692 -1.158378647 0.00189031 1.021713016 Gstm2 -0.12707966 0.572554941 -0.445475281 1.952813994 1.856518122 1.561376671 0.00517664 1.865316016 Gstm1 -0.029147714 0.298593425 -0.26944571 0.983159098 0.872028945 0.786125509 0.00721356 1.949464926 Fasn 0.08403202 -0.214149498 0.130117478 1.052480559 0.779734519 1.229308218 0.00383637 0.829422353 Upb1 -0.112438784 -0.137014769 0.249453553 -1.297732445 -1.181999331 -1.495303666 0.00102373 0.184442034 Selenbp2 0.266508271 0.084791964 -0.351300235 -2.040647809 -2.608780781 -2.039865739 0.00107121 0.165425127 Thrsp -0.15001075 0.177999342 -0.027988592 1.54283307 1.603048661 0.927443822 0.00453549 0.612858263 Hyi 0.142635733 -0.183013091 0.040377359 1.325929636 1.119934412 1.181313897 0.00044587 0.053553518 Eci1 -0.119041811 -0.014846366 0.133888177 -0.599970385 -0.555547972 -1.191875541 0.02292305 2.477981171 Aldh1a7 -0.095682449 -0.017781922 0.113464372 0.653424862 0.931724091 1.110750381 0.00356922 0.350756574 Pebp1 -0.06292058
    [Show full text]
  • Aneuploidy: Using Genetic Instability to Preserve a Haploid Genome?
    Health Science Campus FINAL APPROVAL OF DISSERTATION Doctor of Philosophy in Biomedical Science (Cancer Biology) Aneuploidy: Using genetic instability to preserve a haploid genome? Submitted by: Ramona Ramdath In partial fulfillment of the requirements for the degree of Doctor of Philosophy in Biomedical Science Examination Committee Signature/Date Major Advisor: David Allison, M.D., Ph.D. Academic James Trempe, Ph.D. Advisory Committee: David Giovanucci, Ph.D. Randall Ruch, Ph.D. Ronald Mellgren, Ph.D. Senior Associate Dean College of Graduate Studies Michael S. Bisesi, Ph.D. Date of Defense: April 10, 2009 Aneuploidy: Using genetic instability to preserve a haploid genome? Ramona Ramdath University of Toledo, Health Science Campus 2009 Dedication I dedicate this dissertation to my grandfather who died of lung cancer two years ago, but who always instilled in us the value and importance of education. And to my mom and sister, both of whom have been pillars of support and stimulating conversations. To my sister, Rehanna, especially- I hope this inspires you to achieve all that you want to in life, academically and otherwise. ii Acknowledgements As we go through these academic journeys, there are so many along the way that make an impact not only on our work, but on our lives as well, and I would like to say a heartfelt thank you to all of those people: My Committee members- Dr. James Trempe, Dr. David Giovanucchi, Dr. Ronald Mellgren and Dr. Randall Ruch for their guidance, suggestions, support and confidence in me. My major advisor- Dr. David Allison, for his constructive criticism and positive reinforcement.
    [Show full text]
  • Molecular Mechanisms Regulating Copper Balance in Human Cells
    MOLECULAR MECHANISMS REGULATING COPPER BALANCE IN HUMAN CELLS by Nesrin M. Hasan A dissertation submitted to Johns Hopkins University in conformity with the requirements for the degree of Doctor of Philosophy Baltimore, Maryland August 2014 ©2014 Nesrin M. Hasan All Rights Reserved Intended to be blank ii ABSTRACT Precise copper balance is essential for normal growth, differentiation, and function of human cells. Loss of copper homeostasis is associated with heart hypertrophy, liver failure, neuronal de-myelination and other pathologies. The copper-transporting ATPases ATP7A and ATP7B maintain cellular copper homeostasis. In response to copper elevation, they traffic from the trans-Golgi network (TGN) to vesicles where they sequester excess copper for further export. The mechanisms regulating activity and trafficking of ATP7A/7B are not well understood. Our studies focused on determining the role of kinase-mediated phosphorylation in copper induced trafficking of ATP7B, and identifying and characterizing novel regulators of ATP7A. We have shown that Ser- 340/341 region of ATP7B plays an important role in interactions between the N-terminus and the nucleotide-binding domain and that mutations in these residues result in vesicular localization of the protein independent of the intracellular copper levels. We have determined that structural changes that alter the inter-domain interactions initiate exit of ATP7B from the TGN and that the role of copper-induced kinase-mediated hyperphosphorylation might be to maintain an open interface between the domains of ATP7B. In a separate study, seven proteins were identified, which upon knockdown result in increased intracellular copper levels. We performed an initial characterization of the knock-downs and obtained intriguing results indicating that these proteins regulate ATP7A protein levels, post-translational modifications, and copper-dependent trafficking.
    [Show full text]
  • Biological Models of Colorectal Cancer Metastasis and Tumor Suppression
    BIOLOGICAL MODELS OF COLORECTAL CANCER METASTASIS AND TUMOR SUPPRESSION PROVIDE MECHANISTIC INSIGHTS TO GUIDE PERSONALIZED CARE OF THE COLORECTAL CANCER PATIENT By Jesse Joshua Smith Dissertation Submitted to the Faculty of the Graduate School of Vanderbilt University In partial fulfillment of the requirements For the degree of DOCTOR OF PHILOSOPHY In Cell and Developmental Biology May, 2010 Nashville, Tennessee Approved: Professor R. Daniel Beauchamp Professor Robert J. Coffey Professor Mark deCaestecker Professor Ethan Lee Professor Steven K. Hanks Copyright 2010 by Jesse Joshua Smith All Rights Reserved To my grandparents, Gladys and A.L. Lyth and Juanda Ruth and J.E. Smith, fully supportive and never in doubt. To my amazing and enduring parents, Rebecca Lyth and Jesse E. Smith, Jr., always there for me. .my sure foundation. To Jeannine, Bill and Reagan for encouragement, patience, love, trust and a solid backing. To Granny George and Shawn for loving support and care. And To my beautiful wife, Kelly, My heart, soul and great love, Infinitely supportive, patient and graceful. ii ACKNOWLEDGEMENTS This work would not have been possible without the financial support of the Vanderbilt Medical Scientist Training Program through the Clinical and Translational Science Award (Clinical Investigator Track), the Society of University Surgeons-Ethicon Scholarship Fund and the Surgical Oncology T32 grant and the Vanderbilt Medical Center Section of Surgical Sciences and the Department of Surgical Oncology. I am especially indebted to Drs. R. Daniel Beauchamp, Chairman of the Section of Surgical Sciences, Dr. James R. Goldenring, Vice Chairman of Research of the Department of Surgery, Dr. Naji N.
    [Show full text]
  • UGT1A6 (NM 205862) Human Recombinant Protein Product Data
    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for TP305752 UGT1A6 (NM_205862) Human Recombinant Protein Product data: Product Type: Recombinant Proteins Description: Recombinant protein of human UDP glucuronosyltransferase 1 family, polypeptide A6 (UGT1A6), transcript variant 2 Species: Human Expression Host: HEK293T Tag: C-Myc/DDK Predicted MW: 29.5 kDa Concentration: >50 ug/mL as determined by microplate BCA method Purity: > 80% as determined by SDS-PAGE and Coomassie blue staining Buffer: 25 mM Tris.HCl, pH 7.3, 100 mM glycine, 10% glycerol Preparation: Recombinant protein was captured through anti-DDK affinity column followed by conventional chromatography steps. Storage: Store at -80°C. Stability: Stable for 12 months from the date of receipt of the product under proper storage and handling conditions. Avoid repeated freeze-thaw cycles. RefSeq: NP_995584 Locus ID: 54578 UniProt ID: Q5DT01 RefSeq Size: 1691 Cytogenetics: 2q37.1 RefSeq ORF: 1599 Synonyms: GNT1; HLUGP; HLUGP1; hUG-BR1; UDPGT; UDPGT 1-6; UGT-1A; UGT-1C; UGT-1E; UGT-1F; UGT1; UGT1-01; UGT1-03; UGT1-05; UGT1-06; UGT1.1; UGT1.3; UGT1.5; UGT1.6; UGT1A; UGT1A1; UGT1A3; UGT1A5; UGT1A6S; UGT1C; UGT1E; UGT1F This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 1 / 2 UGT1A6 (NM_205862) Human Recombinant Protein – TP305752 Summary: This gene encodes a UDP-glucuronosyltransferase, an enzyme of the glucuronidation pathway that transforms small lipophilic molecules, such as steroids, bilirubin, hormones, and drugs, into water-soluble, excretable metabolites.
    [Show full text]
  • Endogenous Protein Interactome of Human UDP-Glucuronosyltransferases Exposed by Untargeted Proteomics
    ORIGINAL RESEARCH published: 03 February 2017 doi: 10.3389/fphar.2017.00023 Endogenous Protein Interactome of Human UDP-Glucuronosyltransferases Exposed by Untargeted Proteomics Michèle Rouleau, Yannick Audet-Delage, Sylvie Desjardins, Mélanie Rouleau, Camille Girard-Bock and Chantal Guillemette * Pharmacogenomics Laboratory, Canada Research Chair in Pharmacogenomics, Faculty of Pharmacy, Centre Hospitalier Universitaire de Québec Research Center, Laval University, Québec, QC, Canada The conjugative metabolism mediated by UDP-glucuronosyltransferase enzymes (UGTs) significantly influences the bioavailability and biological responses of endogenous molecule substrates and xenobiotics including drugs. UGTs participate in the regulation of cellular homeostasis by limiting stress induced by toxic molecules, and by Edited by: controlling hormonal signaling networks. Glucuronidation is highly regulated at genomic, Yuji Ishii, transcriptional, post-transcriptional and post-translational levels. However, the UGT Kyushu University, Japan protein interaction network, which is likely to influence glucuronidation, has received Reviewed by: little attention. We investigated the endogenous protein interactome of human UGT1A Ben Lewis, Flinders University, Australia enzymes in main drug metabolizing non-malignant tissues where UGT expression is Shinichi Ikushiro, most prevalent, using an unbiased proteomics approach. Mass spectrometry analysis Toyama Prefectural University, Japan of affinity-purified UGT1A enzymes and associated protein complexes in liver,
    [Show full text]
  • The Key to the Nornicotine Enantiomeric Composition in Tobacco Leaf
    University of Kentucky UKnowledge Theses and Dissertations--Plant and Soil Sciences Plant and Soil Sciences 2012 ENANTIOSELECTIVE DEMETHYLATION: THE KEY TO THE NORNICOTINE ENANTIOMERIC COMPOSITION IN TOBACCO LEAF Bin Cai University of Kentucky, [email protected] Right click to open a feedback form in a new tab to let us know how this document benefits ou.y Recommended Citation Cai, Bin, "ENANTIOSELECTIVE DEMETHYLATION: THE KEY TO THE NORNICOTINE ENANTIOMERIC COMPOSITION IN TOBACCO LEAF" (2012). Theses and Dissertations--Plant and Soil Sciences. 5. https://uknowledge.uky.edu/pss_etds/5 This Doctoral Dissertation is brought to you for free and open access by the Plant and Soil Sciences at UKnowledge. It has been accepted for inclusion in Theses and Dissertations--Plant and Soil Sciences by an authorized administrator of UKnowledge. For more information, please contact [email protected]. STUDENT AGREEMENT: I represent that my thesis or dissertation and abstract are my original work. Proper attribution has been given to all outside sources. I understand that I am solely responsible for obtaining any needed copyright permissions. I have obtained and attached hereto needed written permission statements(s) from the owner(s) of each third-party copyrighted matter to be included in my work, allowing electronic distribution (if such use is not permitted by the fair use doctrine). I hereby grant to The University of Kentucky and its agents the non-exclusive license to archive and make accessible my work in whole or in part in all forms of media, now or hereafter known. I agree that the document mentioned above may be made available immediately for worldwide access unless a preapproved embargo applies.
    [Show full text]
  • PHASE II DRUG METABOLIZING ENZYMES Petra Jancovaa*, Pavel Anzenbacherb,Eva Anzenbacherova
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2010 Jun; 154(2):103–116. 103 © P. Jancova, P. Anzenbacher, E. Anzenbacherova PHASE II DRUG METABOLIZING ENZYMES Petra Jancovaa*, Pavel Anzenbacherb, Eva Anzenbacherovaa a Department of Medical Chemistry and Biochemistry, Faculty of Medicine and Dentistry, Palacky University, Hnevotinska 3, 775 15 Olomouc, Czech Republic b Department of Pharmacology, Faculty of Medicine and Dentistry, Palacky University, Hnevotinska 3, 775 15 Olomouc E-mail: [email protected] Received: March 29, 2010; Accepted: April 20, 2010 Key words: Phase II biotransformation/UDP-glucuronosyltransferases/Sulfotransferases, N-acetyltransferases/Glutathione S-transferases/Thiopurine S-methyl transferase/Catechol O-methyl transferase Background. Phase II biotransformation reactions (also ‘conjugation reactions’) generally serve as a detoxifying step in drug metabolism. Phase II drug metabolising enzymes are mainly transferases. This review covers the major phase II enzymes: UDP-glucuronosyltransferases, sulfotransferases, N-acetyltransferases, glutathione S-transferases and methyltransferases (mainly thiopurine S-methyl transferase and catechol O-methyl transferase). The focus is on the presence of various forms, on tissue and cellular distribution, on the respective substrates, on genetic polymorphism and finally on the interspecies differences in these enzymes. Methods and Results. A literature search using the following databases PubMed, Science Direct and EBSCO for the years, 1969–2010. Conclusions. Phase II drug metabolizing enzymes play an important role in biotransformation of endogenous compounds and xenobiotics to more easily excretable forms as well as in the metabolic inactivation of pharmacologi- cally active compounds. Reduced metabolising capacity of Phase II enzymes can lead to toxic effects of clinically used drugs. Gene polymorphism/ lack of these enzymes may often play a role in several forms of cancer.
    [Show full text]